Clinical trials: Cancer Stem Cells
Renal Cell Cancer
Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Primary Objectives: 1. To compare the overall survival of metastatic renal cell carcinoma (RCC) patients undergoing HLA-matched related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation (NST) using…
- Trial name
- NCT00429026
- Testing
- Fludarabine, Melphalan, Cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Bone Cancer, Bone Diseases
Massive Implants the Next Generation
The study will review the use of massive segmental replacements in the femur, which have a porous collar with and without HA, and autologous stem cell augment. This is a randomised controlled trial.
- Trial name
- MING (NCT03905174)
- Testing
- custom made device
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Iva Hauptmannova
Multiple Myeloma, Relapsed Cancer
Plan Development for Giving Teclistamab in the Outpatient Setting
This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient…
- Conditions
- Multiple Myeloma, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT06251076
- Testing
- Teclistamab, Tocilizumab
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Chronic Lymphocytic Leukemia
Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia
RATIONALE: Giving chemotherapy before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00275015
- Testing
- filgrastim, carmustine, cyclophosphamide
- Where
- 53 sites in Austria, Germany
- Volunteers
- 169 people
- Sponsor
- German CLL Study Group
Malignant Brain Stem Tumor, Glioma
Anlotinib to Malignant Brainstem Glioma
This study is a single-arm, open-label, phase II study of anlotinib combined with radiation in the treatment of patients with malignant brainstem glioma.
- Trial name
- NCT04668508
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang Cancer Hospital
Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections
Evaluation of CMV/EBV-CMI in Haploid HSCT
The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for…
- Conditions
- Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- NCT06554197
- Testing
- CMV/EBV-CMI
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
The purpose of this trial is to evaluate a CMV vaccine given to related donor/recipient pairs (donors prior to peripheral blood stem cell donation and CMV-seropositive recipients just before and after transplantation) and…
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma
- Trial name
- NCT00285259
- Testing
- VCL-CB01, Phosphate-buffered Saline (PBS)
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Astellas Pharma Inc
Childhood Cancers
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
The investigators have developed a parent social-cognitive processing intervention (P-SCIP) to help decrease distress among parent caregivers of children undergoing hematopoietic stem cell transplant (HSCT).
- Trial name
- P-SCIP (NCT00939380)
- Testing
- Behavioral intervention sessions, CD-ROM, DVD and pamphlet
- Where
- 5 sites in United States
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Leukemia, Lymphoma
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00534118
- Testing
- donor lymphocytes
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, HSCT
Comparison of Intralipid With SMOF Lipid Following HSCT
The goal of this clinical trial is to have a successful engraftment in after bone transplantation. Acute leukemia patient of both sexes aged 2 to 18 years, who are transplant candidates, participate in this study.
- Trial name
- NCT06625372
- Testing
- SMOF lipid, INTRALIPIDS
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Shahid Beheshti University
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL
This project is a key clinical research project approved by the Clinical Research Center of the First Affiliated Hospital of Xi 'an Jiaotong University.Tyrosine kinase inhibitors (TKI) combined with chemotherapy and subsequent…
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult
- Trial name
- NCT05024357
- Testing
- Dasatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Graft-versus-Host Disease (GVHD), Hematologic Malignancies
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) in patients undergoing…
- Conditions
- Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation
- Trial name
- GVHD-PTCy (NCT06926595)
- Testing
- Cyclophosphamide (primary intervention for GVHD prophylaxis)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Milton S. Hershey Medical Center
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
This is a prospective, open label, single arm, multi-centre phase II trial aiming to evaluate the safety and efficacy of Enasidenib (investigational product) as prophylactic consolidation in patients with IDH2-mutated MDS, CMML…
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation
- Trial name
- NCT04522895
- Testing
- Enasidenib
- Where
- 11 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Myeloma
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
The purpose of the study is to determine the safety of MLN9708 as maintenance therapy following allogeneic stem cell transplant in patients with multiple myeloma.
- Trial name
- NCT02168101
- Testing
- MLN9708
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- SCRI Development Innovations, LLC
CLL
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL)
17p-/p53-mutated chronic lymphocytic leukemia (CLL) is an orphan disease, accounting for approximately 5% of newly diagnosed CLL. This subgroup of patients has a very poor outcome after chemoimmunotherapy.
- Trial name
- 17p-CLL (NCT01675102)
- Where
- 10 sites in Denmark, Finland and 5 more
- Volunteers
- 41 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of venetoclax when given together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in treating participants with non-Hodgkin lymphoma…
- Conditions
- Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT03583424
- Testing
- Carmustine, Cytarabine, Etoposide
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hodgkins Lymphoma
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP…
- Trial name
- NCT01636388
- Testing
- allogeneic donor derived LMP specific cytotoxic T-lymphocyte
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New York Medical College
Non-Hodgkin's Lymphoma, Multiple Myeloma
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
This is an open-label, single-arm, multicentre study conducted in Spain to estimate the effectiveness of palifermin administered at a dose of 60 mg/kg/day IV for 3 consecutive days before the start of the conditioning regimen and…
- Trial name
- NCT00352703
- Testing
- Kepivance (Palifermin)
- Volunteers
- 145 people
- Sponsor
- Swedish Orphan Biovitrum
Mediastinal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Mediastinal Cancer, Metastatic Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00003941
- Testing
- bleomycin sulfate, filgrastim, cisplatin
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 222 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bone Marrow / Autologous Transplants
Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation
The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.
- Trial name
- NCT01738373
- Testing
- Plerixafor
- Where
- France
- Volunteers
- 262 people
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.